Your Global Leader in Stem Cell Market Research
February 28, 2021, BEIJING–Pharmaron Beijing Co., Limited (Stock Code: 300759.SZ/3759.HK) has entered into a definitive agreement to acquire Allergan Biologics Limited (“The ABL site”) in Liverpool, UK, for US$118.7 million in cash from AbbVie. The transaction is expected to close in the second quarter of 2021, subject to the satisfaction of customary closing conditions. [Read more…]
WuXi AppTec, a leading global provider of R&D- and manufacturing-enabling services in the pharmaceutical, biotechnology and medical device industries, announced that it has completed the acquisition of OXGENE, a pioneering United Kingdom-based contract research and development organization that designs and develops scalable gene therapy technologies. This acquisition enables WuXi AppTec to offer its customers end-to-end support in the creation and development of cutting-edge cell and gene therapies for patients in need worldwide. [Read more…]
HONG KONG, March 2, 2021 — On March 2, 2021, Global Cord Blood Corporation (GCBC) announced that it received a non-binding proposal letter from Alternate Ocean Investment Company Limited (“Alternate Ocean”), a wholly-owned subsidiary of Haitong International Securities Group Limited.
The proposal letter offers for Alternate Ocean, acting on behalf of certain funds and entities that it manages or advises, to acquire all of the outstanding ordinary shares of GCBC for US$5.00 per ordinary share in cash. [Read more…]
